In Reply Dr van den Akker and colleagues propose a possible explanation linking potential deficits in proresolving lipid mediator synthesis to why DHA failed to improve bronchopulmonary dysplasia in both the N3RO1 and MOBYDIck trials.2 As they mentioned, proresolving lipid mediators D and E resolvin series derived from DHA and eicosapentaenoic acid, respectively, have potent roles in the active regulation of inflammatory processes. Arachidonic acid–derived lipoxins appear particularly important for initiating the resolution of the inflammatory cascade.
Marc I, Julien P, Lavoie PM. Maternal Docosahexaenoic Acid Supplementation and Bronchopulmonary Dysplasia in Infants—Reply. JAMA. 2020;324(20):2105. doi:10.1001/jama.2020.19410
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: